Viking Therapeutics logo
Viking Therapeutics VKTX
$ 33.93 -2.5%

Annual report 2025
added 02-11-2026

report update icon

Viking Therapeutics Net Debt 2011-2026 | VKTX

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Viking Therapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-25.6 M -54.3 M -35.1 M - -28.8 M -7.72 M -24.8 M -5.54 M 194 K 14.7 M 813 K 99.1 K 42.8 K -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
14.7 M -54.3 M -13.8 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
BioNTech SE BioNTech SE
BNTX
-973 M $ 91.28 0.11 % $ 27.2 B germanyGermany
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-31.2 M - 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
-5.45 M $ 3.54 -20.81 % $ 238 B britainBritain
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
-25 M - - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
-604 M $ 330.34 3.6 % $ 43.3 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
-3.44 M $ 0.79 1.22 % $ 27.9 M israelIsrael
Atreca Atreca
BCEL
33.1 M - -11.76 % $ 5.79 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
argenx SE argenx SE
ARGX
-89.9 M $ 748.25 0.25 % $ 25 B niderlandNiderland
Завод ДИОД Завод ДИОД
DIOD
-48.6 M - - - russiaRussia
Фармсинтез Фармсинтез
LIFE
612 M - - - russiaRussia
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 0.89 -4.33 % $ 4.85 M chinaChina
Applied Therapeutics Applied Therapeutics
APLT
-49.4 M - - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
131 M - -13.85 % $ 16.1 M usaUSA
AbbVie AbbVie
ABBV
59.5 B $ 206.69 -1.01 % $ 366 B usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-75.5 M $ 4.09 -0.97 % $ 437 M usaUSA
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
-130 M - - $ 2.91 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 3.39 -3.69 % $ 1.01 B canadaCanada
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-206 M $ 8.22 2.37 % $ 225 M israelIsrael
Ardelyx Ardelyx
ARDX
136 M $ 5.97 0.51 % $ 1.44 B usaUSA
Genmab A/S Genmab A/S
GMAB
-6.94 B $ 27.75 0.91 % $ 17.6 B danmarkDanmark
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
-33.6 M - - $ 7.29 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
5.36 B $ 8.23 -0.12 % $ 6.83 B spainSpain
Akebia Therapeutics Akebia Therapeutics
AKBA
-133 M $ 1.32 -4.35 % $ 339 M usaUSA